Replies to post #885 on Israel-Medical-Healthcare

[genisi]

Kamada signs financing deal with US venture fund Hercules

http://globes-online.com/serveen/globes/docview.asp?did=1000302712&fid=942

The biopharmaceutical firm is in the midst of clinical trials for its AAT inhaler.

Efrat Perez-Harpaz 27 Jan 08 17:42
Biopharmaceutical company Kamada Ltd. (TASE: KMDA) has raised a loan of $20 million from US venture lending fund Hercules Technology Growth Capital Inc. (Nasdaq: HTGC). The company will use part of the loan to repay credit it received from two banks, and will earmark the rest for the financing of clinical trials and its strategic program for the next few years.

Hercules Technology specializes in providing venture debt and equity to venture capital and private equity backed technology and life science companies at all stages. The fund's loan to Kamada will bear either annual interest of 10.6%, or the prime rate as published in the "Wall Street Journal" plus 2.9%, whichever is higher. Hercules will also have the right, subject to certain conditions, to participate in future private placements by Kamada.

Kamada is currently developing its Alpha-1 Antitrypsin (AAT) aerosol for the treatment of congenital emphysema and cystic fibrosis.

[genisi]

[One more indication for the inhaled version of AAT]

Kamada to begin Phase II AAT trial

http://globes-online.com/serveen/globes/docview.asp?did=1000307960&fid=942

There are more than 100,000 cases of bronchiectasis every year in the US alone.
Efrat Perez-Harpaz 10 Feb 08 13:02

Biopharmaceutical company Kamada Ltd. (TASE: KMDA) will begin Phase II clinical trials of the aerosolized version of its flagship product, Alpha-1 Antitrypsin (AAT), to treat bronchiectasis, which causes localized, irreversible dilatation of part of the bronchial tree. The company obtained European Medicines Agency (EMEA) approval for the trial last year.

Researchers report that there are more than 100,000 cases of bronchiectasis every year in the US alone. Inhaleable AAT is intended to reduce the inflammation in the lungs to prevent deterioration in their functioning.

Kamada said that in view of clinical reports from around the world suggest that AAT is also effective in treating other bronchial diseases, the company was considering developing the drug for these purposes.

In late January, Kamada raised a loan of $20 million from US venture lending fund Hercules Technology Growth Capital Inc. (Nasdaq: HTGC).